UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression

The Journal of clinical investigation, 2018-06, Vol.128 (6), p.2487-2499

2018

Volltextzugriff (PDF)

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

Nature communications, 2022-06, Vol.13 (1), p.3449-3449, Article 3449

2022

Volltextzugriff (PDF)

Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche

Leukemia, 2018-08, Vol.32 (8), p.1739-1750

2018

Volltextzugriff (PDF)

An epigenetic view of B‐cell disorders

Immunology and cell biology, 2015-03, Vol.93 (3), p.253-260

2015

Volltextzugriff (PDF)

In Situ Characterization of Chromatin Landscape in Progression of Smoldering Precursor Stage to Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.4222-4223

2022

Volltextzugriff (PDF)

Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells

Blood, 2022-11, Vol.140 (Supplement 1), p.860-861

2022

Volltextzugriff (PDF)

Identification of a Novel Epigenetic Mechanism of MYC Deregulation in Smoldering and Newly Diagnosed Multiple Myeloma Patients

Blood, 2021-11, Vol.138 (Supplement 1), p.504-504

2021

Volltextzugriff (PDF)

P-411 Large-scale single-cell dissection of immune dysregulation in patients with monoclonal gammopathies

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S267-S268

2023

Volltextzugriff (PDF)

P-101 Single-cell RNA sequencing of 1.3 million plasma cells from patients with MGUS and SMM

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S90-S90

2023

Volltextzugriff (PDF)

Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.4204-4206

2022

Volltextzugriff (PDF)

Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM

Blood, 2022-11, Vol.140 (Supplement 1), p.7158-7159

2022

Volltextzugriff (PDF)

Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology

Blood, 2022-11, Vol.140 (Supplement 1), p.254-255

2022

Volltextzugriff (PDF)

Dissecting the Epigenetic Landscape of Smoldering, Newly Diagnosed and Relapsed Multiple Myeloma Revealed IRAK3 As a Marker of Disease Progression

Blood, 2018-11, Vol.132 (Supplement 1), p.3896-3896

2018

Volltextzugriff (PDF)

P-097 Single-cell RNA sequencing of circulating tumor cells in precursor myeloma patients reveals early mechanisms of disease dissemination

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S88-S88

2023

Volltextzugriff (PDF)

Abstract 139: Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.139-139

2019

Volltextzugriff (PDF)

P-021: 7C6 is a novel monoclonal antibody that induces enhanced anti-myeloma activity of cytokine induced memory-like (CIML) NK cells by blocking MICA/B shedding and antibodydependent cell cytotoxicity

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S47-S48

2022

Volltextzugriff (PDF)

Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma

Blood, 2018-11, Vol.132 (Supplement 1), p.2603-2603

2018

Volltextzugriff (PDF)

Epigenetic regulation of gene expression in progression of multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2019-10, Vol.19 (10), p.e74-e74

2019

Volltextzugriff (PDF)

Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression

The Journal of clinical investigation, 2018-06, Vol.128 (6), p.2487-2499

2018

Volltextzugriff (PDF)

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood, 2018-11, Vol.132 (Supplement 1), p.154-154

2018

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche

An epigenetic view of B‐cell disorders

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

In Situ Characterization of Chromatin Landscape in Progression of Smoldering Precursor Stage to Multiple Myeloma

Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells

Identification of a Novel Epigenetic Mechanism of MYC Deregulation in Smoldering and Newly Diagnosed Multiple Myeloma Patients

P-411 Large-scale single-cell dissection of immune dysregulation in patients with monoclonal gammopathies

P-101 Single-cell RNA sequencing of 1.3 million plasma cells from patients with MGUS and SMM

Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma

Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM

Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology

Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation

Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes

Dissecting the Epigenetic Landscape of Smoldering, Newly Diagnosed and Relapsed Multiple Myeloma Revealed IRAK3 As a Marker of Disease Progression

P-097 Single-cell RNA sequencing of circulating tumor cells in precursor myeloma patients reveals early mechanisms of disease dissemination

Abstract 139: Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

P-021: 7C6 is a novel monoclonal antibody that induces enhanced anti-myeloma activity of cytokine induced memory-like (CIML) NK cells by blocking MICA/B shedding and antibodydependent cell cytotoxicity

Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma

Epigenetic regulation of gene expression in progression of multiple myeloma

Inhibition of MICA and MICB shedding enhances memory-like NK cell-mediated cytotoxicity against multiple myeloma

Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Suchergebnisse filtern